Plaintiff May Proceed With Sulindac Injury Claims

PROVIDENCE, R.I. - A New Hampshire federal judge has allowed a plaintiff to proceed with claims that the anti-inflammatory drug Sulindac caused her to contract toxic epidermal necrolysis, finding a triable issue as to whether the drug is unreasonably dangerous. Bartlett v. Mutual Pharmaceutical Company Inc., No. CV-08-358-JL (D. R.I.).

However, in the July 12 order, Judge Joseph Laplante of the U.S. District Court for the District of New Hampshire granted Mutual Pharmaceutical Company Inc. summary judgment on the failure-to-warn claims, noting that the plaintiff's physician did not review the drug's label before prescribing the drug.

In December 2004, Karen …